Van beleggers
voor beleggers
desktop iconMarkt Monitor

Inloggen

  • Geen account? Registreren

Wachtwoord vergeten?

Aandeel Merus NV OTC:MRUS.Q, NL0011606264

  • 23,590 21 sep 2021 22:00
  • +0,540 (+2,34%) Dagrange 22,990 - 23,880
  • 174.696 Gem. (3M) 231,4K

Merus NV forum geopend

990 Posts
Pagina: «« 1 ... 42 43 44 45 46 ... 50 »» | Laatste | Omlaag ↓
  1. forum rang 6 Lingus 27 december 2018 22:54
    6-K en F-1 filings: phoenix.corporate-ir.net/phoenix.zhtm...
    Ik maak er uit op dat er gedoe is over het jaarverslag door onduidelijkheid over de deal met Regeneron. Verder lijkt het er op dat Merus 6,3 miljoen aandelen gaat uitgeven, bovenop de 22,75 miljoen bestaande aandelen. Verwatering van ca 28%.

    Ik ben niet al te ervaren in het interpreteren van SEC filings, dus als iemand een betere toelichting kan geven; graag!
  2. rimpel 2 januari 2019 14:19
    Merus N.V. (MRUS) Reports Strategic Collaboration with Betta Pharmaceuticals to Develop & Commercialize MCLA-129 in China
    January 2, 2019 8:02 AM
    Merus N.V. (NASDAQ: MRUS) today announced that it has agreed to grant Betta Pharmaceuticals Co Ltd (300558) an exclusive license to develop and commercialize Merus Biclonics® MCLA-129 in China. Merus will retain all rights outside of China.

    Under the terms of the agreement, Betta Pharmaceuticals has agreed to be responsible for clinical development and commercialization of MCLA-129 in China. As a key strategic component of the collaboration, Betta will retain a contract manufacturing organization with experience in filing Initial New Drug (IND) applications with U.S. and European regulatory authorities in order to produce clinical trial materials for the Chinese market and rest of world. Betta will facilitate regulatory filings and early stage clinical trial materials supply for potential use by Merus for development of MCLA-129 outside of China.

    “This latest collaboration is representative of our long term strategy to unlock Biclonics® platform value beyond our core programs,” said Ton Logtenberg, Ph.D., Chief Executive Officer of Merus. “Betta Pharma is a market leader in EGFR inhibitors in China and we anticipate will be a strong partner for Merus in MCLA-129 development.”

    MCLA-129 is a Biclonics® binding to EGFR and cMET for the treatment of solid tumors. EGFR is an important oncogenic driver in many cancers; the upregulation of c-MET signaling has been associated with resistance to EGFR inhibition.

    MCLA-129 has two distinct mechanisms of action. First, Merus’ Dock & Block® mechanism of action blocks the signaling of EGFR as well as c-MET, with the potential to inhibit tumor growth and survival. Second, MCLA-129 utilizes GlymaxX® antibody-dependent cell-mediated cytotoxicity (ADCC)-enhancement technology designed for greater cell-killing potential. Because the Dock & Block and ADCC mechanism of action is based on the co-expression of EGFR and c-MET, it is expected to have less toxicity compared to agents targeting EGFR alone.

    In preclinical studies, MCLA-129 showed a significant reduction in tumor volume for EGFR inhibitor resistant lung cancer models lacking immune cells. Additionally, in cell lines that co-express both EGFR and c-MET, MCLA-129 effectively induced tumor cell lysis at low antibody concentrations.

    In addition to receiving an upfront payment, Merus will be eligible to receive payments contingent upon Betta Pharmaceuticals achieving certain specified development and commercial goals in China. Merus will also be eligible to receive tiered royalty payments on sales in China from Betta Pharmaceuticals. Betta Pharmaceuticals will be eligible to receive payments contingent upon Merus achieving certain specified development and commercial goals, and will be eligible to receive tiered royalty payments on sales outside of China from Merus.

    by TaboolaSponsored LinksYou May Like
    The 15 Minute Method - Learn a new language in just 15 min a day
    Babbel
    20 Horrible Signs You Are Not Drinking Enough Water
    TopGearUp.com
    25 Foods You Should Stop Eating Now
    healthyandpretty
    These 15 Foods Will Help You Control Diabetes
    The Inner Beast
    12 Facts How Coconut Oil Will Change Your Life
    12Facts.com
    World War II Pilot's Wife Discovers The Truth After Seven Decades Of Waiting
    Top Womens Mag
    30 Foods You Should Never Eat After Age 30
    Fit and Nutrition
    Get Your Teeth White By Eating These Delicious Foods
    My Healthy Vibe
    Top 20 Most Dangerous Dog Breeds In the World
    TopGentlemen
    19 Ways Guys Can Look More Attractive to Women
    BestWomensMag
    Categories
    Corporate News
    FDA
    Management Comments
    Next Articles
    Merus Announces Strategic Collaboration with Betta Pharmaceuticals to Develop and Commercialize MCLA-129 in China
    January 2, 2019 8:00 AM
    Merus N.V. (MRUS) Model Update At Citi Take

  3. Yearling 7 januari 2019 20:50
    Ik ben al die tijd blijven zitten en heb me bij enkele gelegenheden wel es duchtig tegen de kop geslagen - maar tegen dan was het te laat om er nog uit te stappen, al te veel verlies. Dus nu hopelijk terug upwaarts - ik moet nog tot over de 20 raken voor ik winst heb.
    Gelukkig nog andere biotech in mijn port die wat soelaas boden/bieden (oa Gala, Argx, Mithra)
  4. forum rang 4 ivet 29 januari 2019 18:19
    is idd een koopsignaal...dat soort berichten zijn er voor de buhne.

    De reden is simpel: J&J hebben geen belang via de media te ventileren waar ze in of uitstappen. Het kan verandering van mening of strategie zijn...is hun waarheid en niet persé die van de markt of Merus.

    Zo'n bericht wordt eerder de wereld in gebracht door belanghebbenden...nl zij die willen kopen!
990 Posts
Pagina: «« 1 ... 42 43 44 45 46 ... 50 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord

Direct naar Forum

Merus NV Meer »

Koers 23,590   Verschil +0,54 (+2,34%)
Laag 22,990   Volume 174.696
Hoog 23,880   Gem. Volume 231.448
21 sep 2021 22:00
Premium

KOPEN OF VERKOPEN?

Het laatste advies leest u als IEX Premium-lid

Ontdek Premium

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links